{"success":true,"data":{"pressRelease":{"id":"168633","rtpr_id":"nGNX58TN5G-20261014","ticker":"TRDA","exchange":"NASDAQ","all_tickers":["TRDA"],"title":"Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study","author":"Globe Newswire","published_at":"2026-10-14T11:00:00.219Z","article_body":"-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by\nyear-end 2026 --\n\n-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027\n--\n\nBOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq:\nTRDA) today announced that an independent Data Monitoring Committee (DMC), per\nstudy protocol, has reviewed all available safety and PK data from the eight\nparticipants enrolled in Cohort 2 of the double-blind, placebo-controlled,\nmultiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended\ninitiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in\nCohort 2 and 6 mg/kg in Cohort 1. ELEVATE-44-201 is a Phase 1/2 MAD clinical\nstudy of ENTR-601-44 for the potential treatment of Duchenne muscular\ndystrophy (DMD) in participants with a confirmed mutation in the DMD gene\namenable to exon 44 skipping.\n\n“The independent Data Monitoring Committee’s recommendation to advance to\nCohort 3 at the top dose of 18 mg/kg marks another important step in the\nclinical development of ENTR-601-44,” said Natarajan Sethuraman, PhD,\nPresident of Research and Development at Entrada Therapeutics. “This\nrecommendation allows us to continue dose escalation in the ELEVATE-44-201\nclinical study and deepen our understanding of ENTR-601-44’s safety,\npharmacokinetic and pharmacodynamic profile, as dosing at 18 mg/kg could lead\nto meaningfully higher exposure, dystrophin production and functional benefit.\nWe look forward to receiving data later this year from Cohort 1 participants\nafter one year of treatment in the open-label period, followed by Cohort 2\ndata in the first quarter of 2027.”\n\nAbout the ELEVATE-44-201 Phase 1/2 Study\nELEVATE-44-201 is a global, two-part, randomized, double-blind,\nplacebo-controlled Phase 1/2 study evaluating the safety, tolerability and\neffectiveness of ENTR-601-44 in ambulatory participants aged four to 20 with\nDuchenne who are amenable to exon 44 skipping. The multiple ascending dose\n(MAD) Part A portion of the study is evaluating the safety, pharmacokinetics,\npharmacodynamics and functional parameters following intravenous\nadministration of ENTR-601-44 to study participants in three cohorts at sites\nin the U.K. and EU.\n\nAbout ENTR-601-44\nENTR-601-44 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated\noligonucleotide that has a sequence designed and optimized for people with a\nconfirmed mutation in the DMD gene that is amenable to exon 44 skipping, which\ncomprises approximately eight percent of the Duchenne patient population\nglobally. ENTR-601-44 is designed to address the underlying cause of Duchenne,\nfacilitating production of functional dystrophin from the endogenous\n(naturally occurring) DMD gene.\n\nIn December 2025, the U.S. Food and Drug Administration (FDA) granted Rare\nPediatric Disease Designation to ENTR-601-44.\n\nPatients and Their Care Partners\nPatients and their care partners are a critical part of our community, and we\nare committed to keeping them informed and connected. To receive community\nupdates in real time and read today’s update, please visit Community Updates\n(https://www.globenewswire.com/Tracker?data=Nb7mx_qSTBJGYPP0lcswqVm9oyuW-eRMyuNAGHXP8-4L0irWU_6qCVB3CsIHNEihqqDYIQxF7alfx_hv3MA3f2jmjotBHYJ5Y_O6f2tFN7Y=)\non our corporate website.\n\nAbout Duchenne Muscular Dystrophy (DMD)\nDuchenne muscular dystrophy (DMD) is a rare disease caused by mutations in the\nDMD gene, which encodes the dystrophin protein. These mutations lead to\ninadequate dystrophin production. Dystrophin is essential to maintaining the\nstructural integrity and function of muscle cells. Lack of functional\ndystrophin leads to progressive loss of muscle strength, impacting mobility\nand causing heart or respiratory complications that contribute to high\nmortality rates. An estimated 41,000 people in the U.S. and Europe are living\nwith DMD. Of those, approximately 11,500 are amenable to skipping of exon 44,\n45, 50, or 51.\n\nAbout Entrada Therapeutics\nEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to\ntransform the lives of patients by establishing a new class of genetic\nmedicines that engage intracellular targets that have long been considered\ninaccessible. Through proprietary, versatile and modular approaches, Entrada\nis advancing a robust development portfolio of genetic medicines for the\npotential treatment of neuromuscular and inherited retinal diseases, among\nothers. The Company’s lead oligonucleotide programs are in development for\nthe potential treatment of people living with Duchenne muscular dystrophy who\nare exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop\na clinical-stage program, VX-670, for myotonic dystrophy type 1.\n\nFor more information about Entrada, please visit our\nwebsite, www.entradatx.com, and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=9FmAT7MaZRyPhV4woCmmKln13SVoKhKeVdjRhcUFhfpVrxSDK9e-ZBhcjFpBslkSI_ko3OchoBCkP3UNhkGT6knjs1h932UznUIHa0HCph7V3Mz61Qan3iAabcU03P_TyTHqwQ8y_5kpanREZ5H8E1Sog2Gu9V1c1hdha-2g-m8Med3eCn9EvP1KNDC3hNLJuc17wmmcFFiqWmktgjc1S39Nt63KdvDTTI85V8elz6C9I92ihugtxwh4EQwVRw4C).\n\nForward-Looking Statements\n\nThis press release contains express and implied forward-looking statements\nthat involve substantial risks and uncertainties. All statements, other than\nstatements of historical facts, contained in this press release, including\nstatements regarding Entrada’s strategy, future operations, prospects and\nplans, objectives of management, the validation and differentiation of\nEntrada’s approach and EEV platform and its ability to provide a potential\ntreatment for patients, expectations regarding Entrada’s ELEVATE-44-201\nstudy, including the timing of receiving data later this year from Cohort 1\nparticipants after one year of treatment in the open-label period, the timing\nof data from Cohort 2 expected in Q1 2027, the potential for dose escalation\nin the ELEVATE-44-201 study to deepen Entrada’s understanding of\nENTR-601-44’s safety, pharmacokinetic and pharmacodynamic profile and\nfunctional benefits and the ability of the MAD Part A portion of the study to\nevaluate the safety, pharmacokinetics, pharmacodynamics and functional\nparameters of ENTR-601-44, expectations regarding ENTR-601-44, including the\nability for dosing at 18 mg/kg to lead to meaningfully higher exposure,\ndystrophin production and functional benefit, and the potential for\nENTR-601-44 to address the underlying cause of DMD, facilitating production of\nfunctional dystrophin from the endogenous (naturally occurring) DMD gene, the\npotential therapeutic benefits of Entrada’s EEV product candidates,\nincluding and the continued development and advancement of ENTR-601-44,\nENTR-601-45, ENTR-601-50, and ENTR-601-51 for the treatment of DMD and the\npartnered product candidate VX-670 for the potential treatment of DM1, the\nability to continue to expand and develop additional therapeutic programs and\nmodalities, including the potential treatment of neuromuscular and inherited\nretinal diseases, constitute forward-looking statements within the meaning of\nThe Private Securities Litigation Reform Act of 1995. The words\n“anticipate,” “believe,” “continue,” “could,” “estimate,”\n“expect,” “intend,” “may,” “might,” “objective,”\n“ongoing,” “plan,” “predict,” “project,” “potential,”\n“should,” or “would,” or the negative of these terms, or other\ncomparable terminology are intended to identify forward-looking statements,\nalthough not all forward-looking statements contain these identifying words.\nEntrada may not actually achieve the plans, intentions or expectations\ndisclosed in these forward-looking statements, and you should not place undue\nreliance on these forward-looking statements. Actual results or events could\ndiffer materially from the plans, intentions and expectations disclosed in\nthese forward-looking statements as a result of various important factors,\nincluding: uncertainties inherent in the identification and development of\nproduct candidates, including the conduct of research activities and the\ninitiation and completion of preclinical studies and clinical studies;\nuncertainties as to the availability and timing of results from preclinical\nand clinical studies; the timing of and Entrada’s ability to submit and\nobtain regulatory clearance and initiate clinical studies; whether results\nfrom preclinical studies or clinical studies will be predictive of the results\nof later preclinical studies and clinical studies; whether Entrada’s cash\nresources will be sufficient to fund the Company’s foreseeable and\nunforeseeable operating expenses and capital expenditure requirements; as well\nas the risks and uncertainties identified in Entrada’s filings with the\nSecurities and Exchange Commission (SEC), including the Company’s most\nrecent Form 10-K and in subsequent filings Entrada may make with the SEC. In\naddition, the forward-looking statements included in this press release\nrepresent Entrada’s views as of the date of this press release. Entrada\nanticipates that subsequent events and developments will cause its views to\nchange. However, while Entrada may elect to update these forward-looking\nstatements at some point in the future, it specifically disclaims any\nobligation to do so. These forward-looking statements should not be relied\nupon as representing Entrada’s views as of any date subsequent to the date\nof this press release.\n\nInvestor Contact\nDoug Snow\nHead of Investor Relations\ndsnow@entradatx.com\n\nPatient Advocacy Contact\nSarah Friedhoff\nHead of Patient Advocacy\npatientadvocacy@entradatx.com\n\nMedia Contact\nMegan Prock McGrath\nCTD Comms, LLC\nmegan@ctdcomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/77a7db51-bcfe-41a6-b2b5-9b281921f81c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX58TN5G-20261014","title":"Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study","author":"Globe Newswire","ticker":"TRDA","created":"2026-10-14T11:00:00.219Z","tickers":["TRDA"],"exchange":"NASDAQ","article_body":"-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by\nyear-end 2026 --\n\n-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027\n--\n\nBOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq:\nTRDA) today announced that an independent Data Monitoring Committee (DMC), per\nstudy protocol, has reviewed all available safety and PK data from the eight\nparticipants enrolled in Cohort 2 of the double-blind, placebo-controlled,\nmultiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended\ninitiating Cohort 3 at the top dose of 18 mg/kg, an increase from 12 mg/kg in\nCohort 2 and 6 mg/kg in Cohort 1. ELEVATE-44-201 is a Phase 1/2 MAD clinical\nstudy of ENTR-601-44 for the potential treatment of Duchenne muscular\ndystrophy (DMD) in participants with a confirmed mutation in the DMD gene\namenable to exon 44 skipping.\n\n“The independent Data Monitoring Committee’s recommendation to advance to\nCohort 3 at the top dose of 18 mg/kg marks another important step in the\nclinical development of ENTR-601-44,” said Natarajan Sethuraman, PhD,\nPresident of Research and Development at Entrada Therapeutics. “This\nrecommendation allows us to continue dose escalation in the ELEVATE-44-201\nclinical study and deepen our understanding of ENTR-601-44’s safety,\npharmacokinetic and pharmacodynamic profile, as dosing at 18 mg/kg could lead\nto meaningfully higher exposure, dystrophin production and functional benefit.\nWe look forward to receiving data later this year from Cohort 1 participants\nafter one year of treatment in the open-label period, followed by Cohort 2\ndata in the first quarter of 2027.”\n\nAbout the ELEVATE-44-201 Phase 1/2 Study\nELEVATE-44-201 is a global, two-part, randomized, double-blind,\nplacebo-controlled Phase 1/2 study evaluating the safety, tolerability and\neffectiveness of ENTR-601-44 in ambulatory participants aged four to 20 with\nDuchenne who are amenable to exon 44 skipping. The multiple ascending dose\n(MAD) Part A portion of the study is evaluating the safety, pharmacokinetics,\npharmacodynamics and functional parameters following intravenous\nadministration of ENTR-601-44 to study participants in three cohorts at sites\nin the U.K. and EU.\n\nAbout ENTR-601-44\nENTR-601-44 is a proprietary Endosomal Escape Vehicle (EEV™)-conjugated\noligonucleotide that has a sequence designed and optimized for people with a\nconfirmed mutation in the DMD gene that is amenable to exon 44 skipping, which\ncomprises approximately eight percent of the Duchenne patient population\nglobally. ENTR-601-44 is designed to address the underlying cause of Duchenne,\nfacilitating production of functional dystrophin from the endogenous\n(naturally occurring) DMD gene.\n\nIn December 2025, the U.S. Food and Drug Administration (FDA) granted Rare\nPediatric Disease Designation to ENTR-601-44.\n\nPatients and Their Care Partners\nPatients and their care partners are a critical part of our community, and we\nare committed to keeping them informed and connected. To receive community\nupdates in real time and read today’s update, please visit Community Updates\n(https://www.globenewswire.com/Tracker?data=Nb7mx_qSTBJGYPP0lcswqVm9oyuW-eRMyuNAGHXP8-4L0irWU_6qCVB3CsIHNEihqqDYIQxF7alfx_hv3MA3f2jmjotBHYJ5Y_O6f2tFN7Y=)\non our corporate website.\n\nAbout Duchenne Muscular Dystrophy (DMD)\nDuchenne muscular dystrophy (DMD) is a rare disease caused by mutations in the\nDMD gene, which encodes the dystrophin protein. These mutations lead to\ninadequate dystrophin production. Dystrophin is essential to maintaining the\nstructural integrity and function of muscle cells. Lack of functional\ndystrophin leads to progressive loss of muscle strength, impacting mobility\nand causing heart or respiratory complications that contribute to high\nmortality rates. An estimated 41,000 people in the U.S. and Europe are living\nwith DMD. Of those, approximately 11,500 are amenable to skipping of exon 44,\n45, 50, or 51.\n\nAbout Entrada Therapeutics\nEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to\ntransform the lives of patients by establishing a new class of genetic\nmedicines that engage intracellular targets that have long been considered\ninaccessible. Through proprietary, versatile and modular approaches, Entrada\nis advancing a robust development portfolio of genetic medicines for the\npotential treatment of neuromuscular and inherited retinal diseases, among\nothers. The Company’s lead oligonucleotide programs are in development for\nthe potential treatment of people living with Duchenne muscular dystrophy who\nare exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop\na clinical-stage program, VX-670, for myotonic dystrophy type 1.\n\nFor more information about Entrada, please visit our\nwebsite, www.entradatx.com, and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=9FmAT7MaZRyPhV4woCmmKln13SVoKhKeVdjRhcUFhfpVrxSDK9e-ZBhcjFpBslkSI_ko3OchoBCkP3UNhkGT6knjs1h932UznUIHa0HCph7V3Mz61Qan3iAabcU03P_TyTHqwQ8y_5kpanREZ5H8E1Sog2Gu9V1c1hdha-2g-m8Med3eCn9EvP1KNDC3hNLJuc17wmmcFFiqWmktgjc1S39Nt63KdvDTTI85V8elz6C9I92ihugtxwh4EQwVRw4C).\n\nForward-Looking Statements\n\nThis press release contains express and implied forward-looking statements\nthat involve substantial risks and uncertainties. All statements, other than\nstatements of historical facts, contained in this press release, including\nstatements regarding Entrada’s strategy, future operations, prospects and\nplans, objectives of management, the validation and differentiation of\nEntrada’s approach and EEV platform and its ability to provide a potential\ntreatment for patients, expectations regarding Entrada’s ELEVATE-44-201\nstudy, including the timing of receiving data later this year from Cohort 1\nparticipants after one year of treatment in the open-label period, the timing\nof data from Cohort 2 expected in Q1 2027, the potential for dose escalation\nin the ELEVATE-44-201 study to deepen Entrada’s understanding of\nENTR-601-44’s safety, pharmacokinetic and pharmacodynamic profile and\nfunctional benefits and the ability of the MAD Part A portion of the study to\nevaluate the safety, pharmacokinetics, pharmacodynamics and functional\nparameters of ENTR-601-44, expectations regarding ENTR-601-44, including the\nability for dosing at 18 mg/kg to lead to meaningfully higher exposure,\ndystrophin production and functional benefit, and the potential for\nENTR-601-44 to address the underlying cause of DMD, facilitating production of\nfunctional dystrophin from the endogenous (naturally occurring) DMD gene, the\npotential therapeutic benefits of Entrada’s EEV product candidates,\nincluding and the continued development and advancement of ENTR-601-44,\nENTR-601-45, ENTR-601-50, and ENTR-601-51 for the treatment of DMD and the\npartnered product candidate VX-670 for the potential treatment of DM1, the\nability to continue to expand and develop additional therapeutic programs and\nmodalities, including the potential treatment of neuromuscular and inherited\nretinal diseases, constitute forward-looking statements within the meaning of\nThe Private Securities Litigation Reform Act of 1995. The words\n“anticipate,” “believe,” “continue,” “could,” “estimate,”\n“expect,” “intend,” “may,” “might,” “objective,”\n“ongoing,” “plan,” “predict,” “project,” “potential,”\n“should,” or “would,” or the negative of these terms, or other\ncomparable terminology are intended to identify forward-looking statements,\nalthough not all forward-looking statements contain these identifying words.\nEntrada may not actually achieve the plans, intentions or expectations\ndisclosed in these forward-looking statements, and you should not place undue\nreliance on these forward-looking statements. Actual results or events could\ndiffer materially from the plans, intentions and expectations disclosed in\nthese forward-looking statements as a result of various important factors,\nincluding: uncertainties inherent in the identification and development of\nproduct candidates, including the conduct of research activities and the\ninitiation and completion of preclinical studies and clinical studies;\nuncertainties as to the availability and timing of results from preclinical\nand clinical studies; the timing of and Entrada’s ability to submit and\nobtain regulatory clearance and initiate clinical studies; whether results\nfrom preclinical studies or clinical studies will be predictive of the results\nof later preclinical studies and clinical studies; whether Entrada’s cash\nresources will be sufficient to fund the Company’s foreseeable and\nunforeseeable operating expenses and capital expenditure requirements; as well\nas the risks and uncertainties identified in Entrada’s filings with the\nSecurities and Exchange Commission (SEC), including the Company’s most\nrecent Form 10-K and in subsequent filings Entrada may make with the SEC. In\naddition, the forward-looking statements included in this press release\nrepresent Entrada’s views as of the date of this press release. Entrada\nanticipates that subsequent events and developments will cause its views to\nchange. However, while Entrada may elect to update these forward-looking\nstatements at some point in the future, it specifically disclaims any\nobligation to do so. These forward-looking statements should not be relied\nupon as representing Entrada’s views as of any date subsequent to the date\nof this press release.\n\nInvestor Contact\nDoug Snow\nHead of Investor Relations\ndsnow@entradatx.com\n\nPatient Advocacy Contact\nSarah Friedhoff\nHead of Patient Advocacy\npatientadvocacy@entradatx.com\n\nMedia Contact\nMegan Prock McGrath\nCTD Comms, LLC\nmegan@ctdcomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/77a7db51-bcfe-41a6-b2b5-9b281921f81c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T11:00:00.292044686Z","server_sent_at_ms":1791975600292},"received_at":"2026-10-14T11:00:00.356Z","source_url":null},"analysis":{"id":"156903","press_release_id":"168633","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Entrada Therapeutics announced that an independent Data Monitoring Committee recommended initiating Cohort 3 of the ELEVATE-44-201 Phase 1/2 study at the top dose of 18 mg/kg, up from 12 mg/kg in Cohort 2.\n\nThe DMC reviewed safety and PK data from eight participants in the double-blind, placebo-controlled multiple-ascending-dose portion of the study of ENTR-601-44, an exon 44-skipping candidate for Duchenne muscular dystrophy.\n\nThe company expects Cohort 1 open-label data by year-end 2026 and Cohort 2 data in Q1 2027; dosing at 18 mg/kg could drive higher exposure, dystrophin production and functional benefit.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"DMC clears top-dose escalation for ENTR-601-44 with no safety concerns; watch Cohort 1 data by year-end as the real catalyst."},"keyFigures":{"drugName":"ENTR-601-44","phaseOfTrial":"Phase 1/2","customDimensions":{"cohort1_dose":"6 mg/kg","cohort2_dose":"12 mg/kg","cohort3_dose":"18 mg/kg","cohort1_data_timing":"by year-end 2026","cohort2_data_timing":"Q1 2027","cohort2_participants":8}},"quotedText":"dosing at 18 mg/kg could lead to meaningfully higher exposure, dystrophin production and functional benefit","namedEntities":{"people":[{"name":"Natarajan Sethuraman","role":"President of Research and Development"},{"name":"Doug Snow","role":"Head of Investor Relations"}],"products":["ENTR-601-44","VX-670","ENTR-601-45","ENTR-601-50","ENTR-601-51"],"companies":[{"name":"Entrada Therapeutics, Inc.","ticker":"TRDA","relationship":"filer"},{"name":"CTD Comms, LLC","relationship":"media contact agency"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"An independent DMC cleared dose escalation to the top 18 mg/kg cohort with no safety stop, a modestly positive de-risking signal for ENTR-601-44. No efficacy data yet; real catalysts are Cohort 1 data by year-end 2026 and Cohort 2 data in Q1 2027."},"tickerRelevance":{"others":[],"primary":"TRDA"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"clinical-stage small-cap biotech","eventGravity":"routine DMC dose-escalation clearance, no efficacy data","upcomingCatalysts":["Cohort 1 data year-end 2026","Cohort 2 data Q1 2027"]}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Entrada Therapeutics announced that an independent Data Monitoring Committee recommended initiating Cohort 3 of the ELEVATE-44-201 Phase 1/2 study at the top dose of 18 mg/kg, up from 12 mg/kg in Cohort 2.\n\nThe DMC reviewed safety and PK data from eight participants in the double-blind, placebo-controlled multiple-ascending-dose portion of the study of ENTR-601-44, an exon 44-skipping candidate for Duchenne muscular dystrophy.\n\nThe company expects Cohort 1 open-label data by year-end 2026 and Cohort 2 data in Q1 2027; dosing at 18 mg/kg could drive higher exposure, dystrophin production and functional benefit.","key_figures":{"drugName":"ENTR-601-44","phaseOfTrial":"Phase 1/2","customDimensions":{"cohort1_dose":"6 mg/kg","cohort2_dose":"12 mg/kg","cohort3_dose":"18 mg/kg","cohort1_data_timing":"by year-end 2026","cohort2_data_timing":"Q1 2027","cohort2_participants":8}},"named_entities":{"people":[{"name":"Natarajan Sethuraman","role":"President of Research and Development"},{"name":"Doug Snow","role":"Head of Investor Relations"}],"products":["ENTR-601-44","VX-670","ENTR-601-45","ENTR-601-50","ENTR-601-51"],"companies":[{"name":"Entrada Therapeutics, Inc.","ticker":"TRDA","relationship":"filer"},{"name":"CTD Comms, LLC","relationship":"media contact agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T11:00:05.970Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"clinical-stage small-cap biotech","eventGravity":"routine DMC dose-escalation clearance, no efficacy data","upcomingCatalysts":["Cohort 1 data year-end 2026","Cohort 2 data Q1 2027"]}},"durationMs":5597,"modelName":"glm-5.3-flashx"}}